A PYMNTS Company

US: AstraZeneca, Ranbaxy can’t derail pay-for-delay case

By  |  November 25, 2014

UK pharmaceutical conglomerate AstraZeneca and India-based generics maker Ranbaxy Laboratories failed to have a landmark lawsuit ended early, say reports, and the companies will continue to face charges of an anticompetitive pay-for-delay agreement.

US District Judge William Young ruled Monday that the companies cannot end the jury trial early despite claims by the companies that the plaintiffs did not provide enough evidence of the alleged pay-for-delay scheme.

The charges surround the medication known as Nexium.

Reports say the case is the first of its kind since the US Supreme Court ruled against Actavis in deciding that pay-for-delay deals can be anticompetitive.

Meanwhile, reports say Teva Pharmaceuticals decided to settle the matter; details of the settlement, however, were not made public.

The trial began last October.

Full content: Bloomberg

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.